MEDICURE INC - MCUJF STOCK NEWS

Medicure reported Q2 2022 results with total net revenue of $5.7 million, up from $5.1 million year-over-year. Revenue from AGGRASTAT® rose to $2.9 million, while ZYPITAMAG® increased to $1.1 million. Marley Drug's revenue decreased slightly to $1.8 million. Adjusted EBITDA was negative $210,000 compared to positive $158,000 in Q2 2021. The net loss widened to $683,000 due to increased R&D costs. Unrestricted cash improved to $4.8 million from $2.5 million. The full results are available on Medicure's website.

Medicure will present its Q2 2022 financial results via conference call on August 25, 2022, at 8:30 AM ET. The financials will be filed on August 24, 2022. The call will discuss Medicure's developments and future outlook, focusing on its cardiovascular products, including AGGRASTAT^® and ZYPITAMAG^®, which are actively marketed in the U.S. through its subsidiary, Medicure Pharma Inc. Interested parties can access the call through the investor relations page of Medicure’s website.

Medicure Inc. announced the results of its Annual General Meeting held on June 16, 2022, where new directors were elected, including James Kinley, and Ernst & Young LLP was re-appointed as auditor. CEO Albert Friesen expressed gratitude toward departing director Manon Harvey. Medicure focuses on pharmaceutical development for the U.S. cardiovascular market, marketing AGGRASTAT® and ZYPITAMAG®. The company operates Marley Drug, a North Carolina pharmacy that serves patients across the U.S., aiming to improve health outcomes and reduce costs.

Medicure reported Q1 2022 results with total net revenue of $5.7 million, up from $4.9 million in Q1 2021. The company saw strong sales from AGGRASTAT® ($2.8 million) and ZYPITAMAG® ($1.0 million), the latter growing significantly from $161,000 in the previous year. Adjusted EBITDA surged to $1.2 million from $31,000, while net income reached $482,000, compared to a loss of $1.0 million a year prior. Medicure appointed Haaris Uddin as CFO, effective June 1, 2022, enhancing its financial leadership.

Medicure reported a substantial increase in total net revenue for the year ended December 31, 2021, reaching $21.7 million, a rise from $11.6 million in 2020. This growth was driven by higher sales of AGGRASTAT® and ZYPITAMAG®, with the latter achieving $3.1 million in revenue compared to $453,000 previously. The company also noted a net loss of $727,000, an improvement from $6.8 million in 2020. Adjusted EBITDA turned positive at $2.1 million, compared to a negative $3.9 million the prior year, reflecting operational improvements and increased revenues.

Medicure Inc. (TSXV: MPH, OTC: MCUJF) is set to announce its 2021 Year End Results on April 28, 2022, during a conference call at 7:30 AM Central Time. The company focuses on developing and commercializing pharmaceuticals for the U.S. cardiovascular market, particularly AGGRASTAT® and ZYPITAMAG®. They also operate Marley Drug, a pharmacy in North Carolina. The conference call will be accessible via the Medicure investor relations page, and management will address questions related to financial results during the Q&A session.

Medicure Inc. has announced the resignation of Chief Financial Officer David Gurvey, effective March 25, 2022. The company expressed gratitude for Gurvey's contributions and initiated a search for a new CFO. Dr. Neil Owens, the current Chief Operating Officer, will serve as the interim CFO. Medicure focuses on developing innovative pharmaceuticals for the U.S. market, with notable products such as AGGRASTAT and ZYPITAMAG. The company is also expanding its e-commerce capabilities for direct patient ordering.

Medicure Inc. (OTC: MCUJF) announces that its subsidiary, Marley Drug, will be the sole mail-order pharmacy for RxSpark™. This partnership aims to enhance access to discounted medications for Americans, particularly in light of COVID-19's impact on healthcare. Marley Drug offers home delivery of over 100 chronic care medications, with options for 6- and 12-month supplies at competitive prices. The initiative seeks to improve patient adherence and reduce overall healthcare costs. The partnership aligns with Medicure's goal of expanding its pharmaceutical reach in the U.S. market.

Medicure Inc. has launched a national E-Commerce pharmacy platform, Marley Drug, aimed at providing affordable medications to over 100 million uninsured Americans. The platform offers FDA-approved medications for home delivery across all 50 states, enabling users to manage their prescription history easily. Customers can purchase medications in extended supply fills of up to 12 months, with prices starting at $37 for 6 months. During the launch, select medications will be available for just $2 per month with free shipping. Medicure aims to enhance healthcare affordability and shareholder value.